Share on StockTwits

Research analysts at Canaccord Genuity increased their target price on shares of EXACT Sciences (NASDAQ:EXAS) from $18.00 to $19.00 in a report released on Wednesday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s price target suggests a potential upside of 15.22% from the company’s current price.

Shares of EXACT Sciences (NASDAQ:EXAS) opened at 16.49 on Wednesday. EXACT Sciences has a 52 week low of $9.53 and a 52 week high of $17.74. The stock has a 50-day moving average of $16.14 and a 200-day moving average of $13.97. The company’s market cap is $1.366 billion.

EXACT Sciences (NASDAQ:EXAS) last released its earnings data on Tuesday, July 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.25) by $0.01. During the same quarter in the previous year, the company posted ($0.19) earnings per share. Analysts expect that EXACT Sciences will post $-1.06 EPS for the current fiscal year.

EXAS has been the subject of a number of other recent research reports. Analysts at Goldman Sachs initiated coverage on shares of EXACT Sciences in a research note on Wednesday, June 4th. They set a “buy” rating and a $19.00 price target on the stock. Separately, analysts at Wedbush downgraded shares of EXACT Sciences from an “outperform” rating to a “neutral” rating in a research note on Friday, May 30th. They now have a $14.00 price target on the stock. They noted that the move was a valuation call. Finally, analysts at JMP Securities cut their price target on shares of EXACT Sciences from $25.00 to $22.00 in a research note on Friday, May 2nd. They now have a “market outperform” rating on the stock. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have issued a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $16.89.

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of colorectal cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.